
News|Videos|September 30, 2025
Number Needed to Treat Analysis of Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia
Author(s)Asher A. Chanan-Khan, MD
Asher Chanan-Khan, MD, discusses an analysis from the ALPINE trial showing that zanubrutinib reduced the number needed to treat to avoid one progression or death compared with ibrutinib in relapsed/refractory chronic lymphocytic leukemia, with results also demonstrating substantial cost savings from a US payer perspective
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































